SAN FRANCISCO, CA--(Marketwire - January 19, 2011) - Medizone International, Inc. (OTCBB: MZEI) (OTCQB: MZEI) announced today that it has entered into a final product development and production agreement for the manufacture of its AsepticSure™ Advanced Oxidative Sterilization Processes, with ADA Innovations of Toronto, Canada.
Edwin Marshall, CEO of Medizone, commented, “Purely from a corporate perspective, ADA is a ‘new kid on the block’ -- but what the development team behind it brings to the table for the future of AsepticSure™, exceeds all of our expectations.”
ADA founders and directors, Mark Costa, B.A. Sc Mechanical Engineering, and Hao (Hawk) Chen, M.S. Biomedical Engineering, bring more than 20 years of high-level experience to this project from the top echelons of industry -- both in the engineering and medical device sectors.
Datascope Patient Monitoring (now Mindray North America), Husky, along with global medical device manufacturing giant, Mindray International, are just three of the big-name corporations on Mark and Hawk’s respective resumes. Others of significance include Vasogen and Hologic.
Marshall commented, “After short-listing five potential manufacturing partners -- each with impressive backgrounds in medical device development -- ADA stood out as a logical choice for us, for two reasons: They were the only group who boasted a depth of knowledge in Ozone based technologies AND experience in medical device design, building and product launch.”
Dr. Michael Shannon, Medizone’s Director of Medical affairs, added, “The dual qualifications that ADA brings to this collaborative venture are not only unique in the medical device industry, but are also essential to the achievement of our end-goal, i.e., the mass production of a device that satisfies all design and operational requirements pertaining to any relevant market sector, anywhere on the planet.”
Edwin Marshall went on to say, “ADA Innovations provides a perfect fit of knowledge, expertise and experience for bringing the AsepticSure™ systems to market.”
“From a compliance point of view,” said Marshall, “our relationship with ADA ensures that the design, content and manufacturing standards of the production units will be regulatory-compliant, not only in North America, but also in the lucrative UK and EU markets.”
“Given that the stringent green regulations applicable to these two regions are some of the toughest in the world, it’s reassuring to say the least,” said Marshall, “that ADA can seamlessly tailor location-specific unit designs to meet and comply with local regulatory standards.”
The AsepticSure™ final-phase development program, already underway, can be broken down into four primary, progressive steps as follows:
- Completion of final commercial design and verification
- Regional regulatory compliance
- Soft product launch involving small scale manufacturing output
- Multi-sector market penetration supported by up-scaled output and the ability to outsource macro manufacturing capacity at the appropriate time
“While the transition from beta to production equipment has taken significantly longer than anticipated a year ago, the ‘wait,’ as they say, ‘has been well worth it,’” said Marshall. “We’re now more confident than ever that our AsepticSure™ product line will far surpass any other form of sterilization technology on the market -- not only in terms of its clinically proven anti-microbial efficacy, but also in its functionality, mobility and cost-effectiveness.”
Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, patient rooms, schools, clean rooms and other critical infrastructure. A government variant is being developed for bio-terrorism countermeasures with additional variants for sports facilities and food processing applications.
This Press Release may contain certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues, the financial requirements of the company to achieve its business objectives, and the need for possible additional funding. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.
For more information, visit: www.medizoneint.com or email: operations@medizoneint.com.
For press information on Medizone, please contact:
Jack Eversull
Investor Relations
The Eversull Group, Inc.
T: 001-972-571-1624
F: 001-214-469-2361
E: Email Contact
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
